Boston Scientific Co. (NYSE:BSX) Shares Bought by Swedbank AB

Swedbank AB increased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,430,925 shares of the medical equipment provider's stock after purchasing an additional 8,246 shares during the period. Swedbank AB owned about 0.10% of Boston Scientific worth $119,912,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. CRA Financial Services LLC raised its holdings in Boston Scientific by 4.3% in the third quarter. CRA Financial Services LLC now owns 2,841 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 117 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its position in Boston Scientific by 9.7% in the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider's stock valued at $115,000 after purchasing an additional 119 shares in the last quarter. Adero Partners LLC increased its position in shares of Boston Scientific by 3.6% in the third quarter. Adero Partners LLC now owns 3,617 shares of the medical equipment provider's stock valued at $303,000 after acquiring an additional 127 shares during the last quarter. Ashton Thomas Securities LLC boosted its holdings in shares of Boston Scientific by 1.3% in the 3rd quarter. Ashton Thomas Securities LLC now owns 9,968 shares of the medical equipment provider's stock valued at $835,000 after buying an additional 129 shares during the last quarter. Finally, CVA Family Office LLC increased its stake in shares of Boston Scientific by 7.4% during the 2nd quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider's stock worth $147,000 after purchasing an additional 131 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Price Performance

Shares of NYSE:BSX traded down $0.75 during trading on Monday, reaching $89.25. The stock had a trading volume of 10,227,334 shares, compared to its average volume of 6,096,185. The stock has a market cap of $131.53 billion, a PE ratio of 73.76, a PEG ratio of 2.65 and a beta of 0.79. Boston Scientific Co. has a 1-year low of $53.93 and a 1-year high of $91.93. The business has a fifty day moving average price of $86.11 and a 200-day moving average price of $80.32. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company had revenue of $4.21 billion for the quarter, compared to analysts' expectations of $4.04 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. Boston Scientific's revenue for the quarter was up 19.3% compared to the same quarter last year. On average, equities analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Sanford C. Bernstein lifted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Evercore ISI increased their price target on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Monday, November 4th. Wells Fargo & Company increased their target price on Boston Scientific from $87.00 to $98.00 and gave the company an "overweight" rating in a research report on Thursday, October 24th. Finally, Citigroup raised their target price on Boston Scientific from $92.00 to $98.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $93.39.

Insiders Place Their Bets

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the transaction, the executive vice president now directly owns 37,468 shares in the company, valued at approximately $3,061,135.60. This represents a 15.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now owns 978 shares of the company's stock, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 328,157 shares of company stock worth $27,894,270 in the last 90 days. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.